Freenome is a biotechnology company revolutionizing cancer detection through advanced blood tests. By combining multiomics analysis with machine learning, they identify cancer at its earliest, most treatable stages. With over $1 billion in funding, Freenome is conducting large-scale clinical trials to validate its technology, starting with colorectal and lung cancer. Their goal is to make early cancer detection routine, saving lives through acc...read more
freenome.com